

JSP Pharmaceutical Manufacturing (Thailand)
Public Company Limited
Registration No. 0107561000480
255, 257 Soi Sathupradit 58, Bangphongphang
Sub-district, Yannawa District, Bangkok

Date: 25 March 2025

Subject: Invitation to the Annual General Meeting of Shareholders for the Year 2025
Dear: Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited
Enclosures:

1. Annual Registration Statement/Annual Report for the year 2024 (Form 56-1 One Report) in QR Code format
2. Detailed Profile of the Candidates to be Elected as the Directors in Place of Directors who are to be Retired by Rotation
3. Detailed Profile and Experience of the Auditors for the Year 2025
4. Proxy Forms (Form A, Form B and Form C)
5. Detailed Profile of the Independent Directors who the Shareholders can Consider Appointing as Proxies
6. Company's Articles of Association in relation to the Shareholders' Meeting
7. Acceptance Form for Attending the Meeting via Electronic Means (E-AGM)
8. Procedures of Registration and Voting via Electronic Means (E-AGM) and Appointment of Proxy

Whereas the Board of Directors of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited (the "Company") has scheduled the Annual General Meeting of Shareholders for the year 2025 to be held on Thursday, 22 April 2025, at 10.00 a.m. via electronic means (E-AGM) only in accordance with the rules as stipulated in the relevant laws to consider matters according to the following agendas:

Agenda 1 **To Acknowledge the Annual Report for the Year 2024**

Objective and Rationale

As Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider the report of the Board of Directors showing the Company's performance in the previous year. Therefore, the Board of Directors had prepared the report of the Board of Directors showing the Company's performance in the year 2024 as shown in the Annual Registration Statement/Annual Report for the year 2024 (Form 56-1 One Report) as sent in QR Code format where the Shareholders can download it in digital format together with this Invitation Letter (Enclosure 1).

Board of Directors' Opinion

The Board of Directors approved and deemed appropriate to propose the Shareholders' Meeting to acknowledge the Company's Annual Report for the year 2024.

Resolution

Since this agenda is for Shareholders' acknowledgement, voting is not required.

Agenda 2

To Consider Approving the Financial Statements for the Year Ended 31 December 2024

Objective and Rationale

As Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider approving the statement of financial position and statement of comprehensive income at the end of the previous fiscal year; and Article 57 of the Company's Articles of Association and Section 112 of the Public Company Act B.E. 2535 (1992) prescribe that the Board of Directors must cause to be made the balance sheet (the statement of financial position) and the profit and loss account (the statement of comprehensive income) at the end of the Company's fiscal year and must submit the Shareholders' Meeting to consider approving them in the Annual General Meeting of Shareholders. The Board of Directors must have such the balance sheet and the profit and loss account to be audited by an auditor before submitting them to the Shareholders' Meeting.

The Board of Directors has prepared the Company's financial statements for the year ended 31 December 2024 which have been audited by the Company's auditor and reviewed by the Audit Committee as shown in the Annual Registration Statement/Annual Report for the year 2024 (Form 56-1 One Report) "Section 3 Financial Statements" in QR Code format where the Shareholders can download it in digital format together with this Invitation Letter (Enclosure 1).

Board of Directors' Opinion

The Board of Directors approved and deemed appropriate to propose the Shareholders' Meeting to consider approving the Company's financial statements for the year ended 31 December 2024, which have been audited by the Company's auditor and reviewed by the Audit Committee.

Summary of significant consolidated financial information (partial)

<i>(Unit: Baht million)</i>	Year 2024	Year 2023
Total assets	1,326.65	1,337.40
Total liabilities	444.13	405.57
Total revenues	824.49	575.58
Net profit (loss)	(33.17)	27.39
Basic earnings (losses) per share (Baht per share)	0.01	(0.004)
Diluted earnings (losses) per share (Baht per share)	0.01	(0.003)

Resolution

The resolution of this agenda shall be approved by the majority vote of the Shareholders who attend the meeting and cast their votes.

Agenda 3

To Consider Approving the Omission of Appropriation of Net Profit to be Legal Reserve for the Performance for the Year Ended 31 December 2024 and Omission of Dividend Payment for the Year 2024

Objective and Rationale

As Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider appropriating profits and fund to be reserve fund; and Article 52 of the Company's Articles of Association and Section 116 of the Public Company Act B.E. 2535 (1992) prescribe that the Company must appropriate part of its annual net profit to be the reserve fund in an amount not less than five percent of the annual net profit less deficit brought

forward (if any) until this reserve fund reaches the amount not less than ten percent of the registered capital.

In addition, Article 49 of the Company's Articles of Association prescribes that it is prohibited to announce the dividend payment except such dividend is paid according to the resolution of the Shareholders' Meeting, and Section 115 of the Public Company Act B.E. 2535 (1992) prescribes that the payment of dividends must be made upon approval by the Shareholders' Meeting.

The Company has policy to pay the dividend at the rate not less than 40 percent of the net profit according to the Company's separate financial statements after deduction of all reserve funds as stipulated in laws and the Company's Articles of Association. However, such dividend payment must not exceed the retained profit according to the Company's separate financial statements. In addition, in case where the Company's separate financial statements have a deficit, the Company will not consider the dividend payment. However, the Company may consider to pay the dividend at the rate lower than the above-mentioned rate depending on the performance, financial position and liquidity of the Company, including the necessity to utilise the working capital for its business operation, the Company's future business expansion plan and other factors relating to the Company's management as deemed appropriate by the Board of Directors.

Pursuant to financial performance for the year ended 31 December 2024, the Company had net loss and deficit in separate financial statements amounting to Baht 34,973,563.09 and Baht 53,464,054.01, respectively.

Summary of dividend payment of the Company

	Year 2024	Year 2023
Net profit (loss) for the year (Baht)	(34,973,563.09)	8,589,287.88
Unappropriated deficit as of 31 December (Baht)	(53,464,054.01)	(2,303,862.41)
Number of shares issued and paid-up as of December (shares)	474,574,921	474,554,900
Dividend paid (Baht)		
- Interim dividend	14,995,741.96	- None -
- Proposed dividend	- None -	- None -
Total dividend paid (Baht)	14,995,741.96	- None -
Dividend per share (Baht per share)		
- Interim dividend	0.0316	- None -
- Proposed dividend	- None -	- None -
Total dividend per share (Baht per share)	0.0316	- None -
Earnings per share (Baht per share)	(0.074)	0.018
Dividend payout ratio	- None -	- None -

Remark: Information excerpted from separate financial statements for the year ended 31 December 2024 (Audited)

The dividend payout ratio was in line with the Company's dividend policy since the Company had net loss and deficit in the separate financial statements for the year ended 31 December 2024.

However, interim dividend paid during 2024 amounting to Baht 14,995,741.96 derived from net profit according to separate interim financial statements for the six-month period ended 30 June 2024 (Reviewed) which reported net profit and unappropriated retained earnings amounting to Baht 22,874,693.38 and Baht 20,570,830.97, respectively. Since the Company had net loss for the year ended 31 December 2024, the Company then omitted dividend for the year 2024.

Board of Directors' Opinion

The Board of Directors approved and deemed appropriate to propose the Shareholders' Meeting to consider approving the omission of appropriation of net profit to be the legal reserve, and omission of the annual dividend payment for the year 2024 since the Company had deficit and net loss in the separate financial statements for the year ended 31 December 2024.

Resolution

The resolution of this agenda shall be approved by the majority vote of the Shareholders who attend the meeting and cast their votes.

Agenda 4 **To Consider Approving Transfer of Legal Reserve and Ordinary Share Premium to Compensate Deficit in the Company's Separate Financial Statements**

Objective and Rationale

As Section 119 of the Public Company Act B.E. 2535 (1992) prescribes that the Company shall able to transfer reserves under Section 51, Section 116 or other reserves to compensate the Company's deficit upon approval from the Shareholders Meeting. The said compensation to deficit must be first from other reserves and then reserve under Section 116 and Section 51, respectively.

According to the Company's separate financial statements for the year ended 31 December 2024 (Audited), the Company had deficit totalled Baht 53,464,054.01. In order to prepare the Company to be ready for dividend payment in the future of the Company has sufficient net profit and cash flows, the Board of Directors considered and deemed appropriate to propose the Shareholders' Meeting to condier approving transfer of legal reserve amounting to Baht 3,861,847.60 and ordinary share premium amounting to Baht 49,602,206.41 to compensate all deficit outstanding. The Company had no other reserves. Following the said transfer of legal reserve and ordinary share premium to compensate deficit, the Company's separate financial statements shall have none of deficit, none of legal reserve, but shall have balance of ordinary share premium amounting to Baht 722,930,059.21. In addition, this compensation shall have no effect to total shareholders' equity of the Company as depicted below:

	<u>Before</u> transfer of legal reserve and ordinary share premium	<u>After</u> transfer of legal reserve and ordinary share premium
<i>Unit: Baht</i>		
Registered share capital	355,931,190.50	355,931,190.50
Issued and paid-up share capital	237,287,460.50	237,287,460.50
Ordinary share premium	772,532,265.62	722,930,059.21
Difference arising from common control transactions	(11,539,170.62)	(11,539,170.62)
Retained earnings – legal reserve	3,861,847.60	-
Unappropriated deficit	(53,464,054.01)	-
Total shareholders' equity	948,678,349.09	948,678,349.09

Board of Directors' Opinion

The Board of Directors approved and deemed appropriate to propose the Shareholders' Meeting to consider approving transfer of legal reserve amounting to Baht 3,861,847.60 and ordinary share premium amounting to Baht

49,602,204.41 to compensate deficit amounting to Baht 53,464,054.01 in the Company's separate financial statements.

Resolution

The resolution of this agenda shall be approved by the majority vote of the Shareholders who attend the meeting and cast their votes, excluding abstentions from the calculation base.

Agenda 5 To Consider Approving the Appointment of Directors in Place of Directors who are to be Retired by Rotation

Objective and Rationale

As Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider electing the directors in place of directors who are to be retired by rotation and Article 18 prescribes that, at every Annual General Meeting of Shareholders, at least one-thirds of the directors shall retire from office. If their number is not a multiple of three, then the number nearest to one-thirds shall retire from office. The directors who have been in office longest shall retire. A retiring director is eligible for re-election.

At the Annual General Meeting of Shareholders for the year 2025, there are 3 directors who are to be retired by rotation as follows:

- | | | |
|-----|------------------------------|----------------------|
| (1) | M.D. Thongchai Thavichachart | Independent Director |
| (2) | Mr. Sittichai Daengprasert | Director |
| (3) | Ms. Jirada Daengprasert | Director |

Board of Directors' Opinion

The Company set aside policy by assigning the Nomination and Remuneration Committee to consider nomination of director with carefully and prudently scrutinised processes in order to propose a person who have knowledge, ability and experience relevant to the Company's businesses. Moreover, the nominated person should have qualification as required by the Company and should have time to fully devote in performing duties for the benefits of the Company's operations. Additionally, the nomination of director of the Company considers variety in board structure and takes relevant skills as per Board Skill Matrix into account, together with other appropriate qualifications and align with the Company's strategies, both short-run and long-run, without limit to gender, race, religion. The nominated person shall not have prohibited characteristics under the laws and good corporate governance principle for listed companies. The Nomination and Remuneration Committee shall then propose the nominated person to the Board of Directors to consider approving and/or propose to the Shareholders' Meeting to approve, as the case may be.

In accordance with the good corporate governance practice in relation to the treatment of the Shareholders' rights, the Company has welcomed the Shareholders' proposals for the agendas and candidates to be elected as directors for the Annual General Meeting of Shareholders for the year 2025 in advance from 16 September 2024 to 1 November 2024 as details disclosed in the Company's website. However, neither agenda nor candidate was proposed by the Shareholders.

The Board of Directors (excluded directors who had interest) has considered and concluded that the nominated directors were considered in compliance with the Company's nomination procedures, had characteristics in accordance with related rules and deemed appropriate with the Company's operations. Furthermore, the person who was proposed to be independent director i.e. M.D. Thongchai Thavichachart, the Board of Directors (excluded director who had interest) has considered and concluded that he had characteristics in accordance with rules about independent director, applicable by laws. Profile of the aforementioned directors are shown in the Detailed Profile of the Candidates to be Elected

as the Directors in Place of Directors who are to be Retired by Rotation as sent together with this Invitation Letter (Enclosure 2).

Hence, the Board of Directors agreed with the Nomination and Remuneration Committee's proposal and then approved and deemed appropriate to propose the Shareholders' Meeting to consider approving the appointment of directors who are to be retired by rotation to resume the director positions for another term of office as follows:

- (1) M.D. Thongchai Thavivhachart to resume the Independent Director position
- (2) Mr. Sittichai Daengprasert to resume the Director position
- (3) Ms. Jirada Daengprasert to resume the Director position

Resolution

The resolution of this agenda shall be approved by the majority vote of the Shareholders who attend the meeting and cast their votes. Whereby, the appointment will be performed separately for each of director.

Agenda 6 To Consider Approving the Determination of Remuneration of Directors and Subcommittees for the Year 2025

Objective and Rationale

As Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider to determine the remuneration of Directors, and Article 34 prescribes that the bonus and remuneration of Directors shall be fixed by the Shareholders' Meeting.

Accordingly, it is deemed appropriate to propose the Shareholders' Meeting to consider approving the determination of remuneration of directors and subcommittees for the year 2025 as per the following details.

(Unit: Baht)	Meeting Allowances			
	Year 2025 (Proposed)		Year 2024 (Previous)	
	Per Time	Per Quarter	Per Time	Per Quarter
Types of Directors				
Chairman of the Board of Directors	40,000	15,000	40,000	15,000
Director and Independent Director	15,000	-	12,000	-
Chairman of the Audit Committee	30,000	10,000	30,000	10,000
Member of the Audit Committee	15,000	-	15,000	-
Chairman of the Risk Management Committee	12,000	-	10,000	-
Member of the Risk Management Committee	10,000	-	7,500	-
Chairman of the Nomination and Remuneration Committee	12,000	-	10,000	-
Member of the Nomination and Remuneration Committee	10,000	-	7,500	-

Remarks:

1. The directors' remuneration above does not apply to directors who are the Company's executives which receive monthly remuneration.
2. The Company is entitled to additionally pay the directors' remuneration as per the Company's annual turnover. The total directors' remuneration shall not exceed 0.25% of the total revenue as per the Company's annual consolidated financial statements.
3. There is neither other remunerations nor other benefits paid to the directors

The Company had criteria and procedures to determine directors' remuneration as follow:

- (1) Consider thoroughly and filtered base on appropriateness
- (2) Compare with reference to average directors' remuneration in similar industry
- (3) Consider the Company's business and profit growth
- (4) Economic conditions
- (5) Current number of the Company's directors

Board of Directors' Opinion

The Board of Directors agreed with the Nomination and Remuneration Committee's proporsal and then approved and deemed appropriate to propose the Shareholders' Meeting to consider approving the determination of remuneration of directors and subcommittees for the year 2025 as proposed.

Resolution

The resolution of this agenda shall be approved by the votes not less than two-thirds of all votes of the Shareholders who attend the meeting.

Agenda 7 To Consider Approving the Appointment of Company's Auditors and Specification of Auditors' Remuneration for the Year 2025

Objective and Rationale

As Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider and appoint the Auditors and specify the auditors' remuneration, and Article 60 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must appoint the auditors every year, and the Shareholders' Meeting may appoint such retired auditors to resume their positions and Article 61 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must specify the auditors' remuneration.

The Audit Committee nominated of auditors by considering past performance, independence, knowledge, experiences and ability to provide good value advices and opined that KPMG Phoomchai Audit Ltd. had appropriate expertise and fees, together with independence. Therefore, it is deemed appropriate to propose the Shareholders' Meeting to consider approving the appointment of the auditors for the year 2025 according to the details as follows:

- (1) Miss Kanokon Phooriphanyawanit Certified Public Accountant No. 10512; or
- (2) Miss Nadsasin Wattanapaisal Certified Public Accountant No. 10767; or
- (3) Miss Sukanya Rodkroh Certified Public Accountant No. 12089,

from KPMG Phoomchai Audit Ltd. or other auditors from the same company, which have qualifications and do not have characteristics as restricted by the laws, to audit and certify the Company's financial statements. Profile and experience of the above-mentioned auditors are shown in the Detailed Profile and Experience of the Auditors for the Year 2025 as sent together with this Invitation Letter (Enclosure 3). Including this appointment, KPMG Phoomchai Audit Ltd. has served as the Company's auditor for 10 years (reporting period from 2016 to 2025). Moreover, the Shareholders' Meeting shall consider approving the specification of the auditors' remuneration as detailed below:

<i>(Unit: Baht)</i>	Year 2025 (Proposed)	Year 2024 (Previous)	Difference
Auditing of financial statements for the year and reviewing of quarterly interim financial statements of the Company (consolidated and separate financial statements)	2,650,000	2,300,000	350,000
Non-audit fee	- None -	- None -	- None -

The audit fees proposed was higher than previous year because higher volume of the Company's transactions. All of the Company's subsidiaries use the same audit office to audit and certify the financial statements. The Board of Directors will oversight the subsidiaries to prepare financial statements in timely manner. In addition, the aforementioned auditors and audit office do not have relationships and/or interest between auditors and the Company, subsidiaries, executives, major shareholders or other related persons.

Board of Directors' Opinion

The Board of Directors agreed with the Audit Committee's proposal and then approved and deemed appropriate to propose the Shareholders' Meeting to consider approving the appointment of auditors for the year 2025 from KPMG Phoomchai Audit Ltd. and specify the auditors' remuneration for the auditing and certifying the Company's consolidated and separate financial statements in the amount not exceeding Baht 2,650,000 (excluding out of pocket expenses and VAT (if any)) as proposed.

Resolution

The resolution of this agenda shall be approved by the majority vote of the Shareholders who attend the meeting and cast their votes.

Agenda 8 To Consider Approving the Additional Amendment of the Company's Objectives and Additional Amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives)

Objective and Rationale

In order to support with the future businesses of the Company, it is deemed appropriate to propose the Shareholders' Meeting to consider approving 7 items of additional amendment to the Company's objectives and additional amendment of the Company's Memorandum of Association, Clause 3. Re: (Objectives) in accordance with Section 31 of the Public Company Act B.E. 2535 (1992) as detailed below:

The Company's objectives no. 31 - 37 added

No. 31 Operate business in relation to private hospital, hospital, polyclinic, Thai traditional medical clinic, applied Thai medical clinic, midwifery and nursing clinic, Chinese traditional medical clinic, medical clinic, dialysis clinic, physical therapy clinic, healthcare clinic, wellness center, healthcare support centre, health treatment and rehabilitation centre, recovery and care centre, nursing home, examine and cure patients, physical therapy planning and caring, training operator in medical and hygiene, together with provide consultancy in relation to medical, hygiene and referral of patients.

No. 32 Operate business in relation to health, beauty, plastic surgery, anti-aging medicine, health and body recovery, health and body therapy. Also, provide administration of business of health, beauty, plastic surgery, anti-aging medicine, health and body recovery, health and body therapy, together with provide consultancy services related to those matters, clinical study, medical experiment for develop and evaluate efficiency, safety and quality of medical product, medicine, vaccine, dietary supplement, medical tool and healthcare product, together with provide services related to clinical study in accordance with global standards and regulations from regulatory agencies.

No. 33 Operate business in relation to manufacture by planting, manufacture without planting, import, export, trade and possess of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and other objects or substances in leaves of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and/or other plants or mushrooms in the same genus as the aforementioned plants or mushrooms for medical purposes, academic, research or plant breeding, producing of certified seed and other benefits in commercial or industrial purposes (when permitted by related agencies and received permission according to Narcotics Substance Type 5 Gazette and Narcotics Substance Type 2 Gazette from the Food and Drug Administration, Ministry of Public Health, and the operations will be aligned with related laws).

No. 34 Operate domestic or abroad business in relation to import, export, purchase and/or trade of seed, certified seed, young plant, fresh trunk, fresh leaf, dried leaf, inflorescences, or other components of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and/or other plants or mushrooms in the same genus as the aforementioned plants or mushrooms, extract substance (including residue) from extraction of Cannabis, Hemp, Kratom, Opium, Herbs, Psilocybe mushroom and/or other plants or mushrooms in the same genus as the aforementioned plants or mushrooms (when permitted by related agencies and received permission according to Narcotics Substance Type 5 Gazette and Narcotics Substance Type 2 Gazette from the Food and Drug Administration, Ministry of Public Health, and the operations will be aligned with related laws).

No. 35 Operate domestic or abroad business in relation to extraction factory, processing factory, import, export and/or trade of product derives from manufacturing, extraction, transforming of Cannabis, Hemp, Kratom, Opium (e.g. raw rubber, Morphine extract and Codeine), Herbs, Psilocybe mushroom (e.g. dried mushroom, grind power mushroom, capsule, fresh leaf, dried leaf, young plant, extract) and/or other plants or mushrooms in the same genus as the aforementioned plants and mushrooms (when received permission according to Narcotics Substance Type 5 Gazette and Narcotics Substance Type 2 Gazette from the Food and Drug Administration, Ministry of Public Health the operations will be aligned with related laws).

No. 36 Operate domestic or abroad business in relation to provide consultancy about manufacturing, import, export of Cannabis, Hemp, Kratom, herb and/or other plants in the same genus as the aforementioned plants (the operations will be aligned with related laws).

No. 37 Invest by holding shares or being partner or participate in project to study, analyse, research or plant breeding, seed production in conjunction with juristic person, fund, organisation or other agencies operate in private or public sectors. Or, being a member of community enterprise registered under the laws and/or agricultural cooperation registered under the laws which operate under coordination and supervision by government agencies for activities about Cannabis, Hemp, Kratom, herb and/or other plants in the same genus as the aforementioned plants (the operations will be aligned with related laws).

Memorandum of Association No. 3 (Objectives) additional amendment

Previously

No. 3 There are 30 objectives of the company

Revised

No. 3 There are 37 objectives of the company

In this regard, the authorities for the registration of additional amendment of the Company's objectives and additional amendment of the Company's Memorandum of Association with the Department of Business Development, Ministry of Commerce, shall be assigned to the Company's authorised directors or the persons assigned by the Company's authorised directors to register in aforementioned matters. In addition, such persons shall have authority to amend and add wordings to be in compliance with the order of the Registrar in order to complete the registration.

Board of Directors' Opinion

The Board of Directors deemed appropriate to propose the Shareholders' Meeting to consider approving the additional amendment of the Company's objectives no. 31 - 37 and additional amendment of the Company's Memorandum of Association, Clause 3 Re: Objectives as mentioned above.

Resolution

The resolution of this agenda shall be approved by the vote not less than three-fourths of the Shareholders who attend the meeting and eligible to vote.

Agenda 9: Other Business (if any)

In addition, the Company determined the name list of the Shareholders who are eligible to attend the Annual General Meeting of Shareholders for the year 2025 on 14 March 2025. In this regard, the Company would like to invite the Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited to attend the Annual General Meeting of Shareholders for the year 2025 by electronic mean (E-AGM) only. The Company shall operate the meeting in accordance with the Company's Articles of Association as details depicted in Enclosure 6.

In case of the Shareholders who wish to attend the meeting and cast the votes by electronic mean (E-AGM) by themselves, please read an instruction to attend the Annual General Meeting of Shareholders for the year 2025 and cast the votes via electronic mean (E-AGM) as appeared in the Enclosure 8 or the Company's website (<https://jsppharma.com/en/shareholder-meeting/>)

In order to protect rights and benefits of the Shareholders if the Shareholders cannot attend the meeting, the Shareholders are able to grant proxy to another person or the Company's independent director as details appeared in the Enclosure 5 to attend the meeting and cast the votes on behalf of the Shareholders. The Shareholders who wish to obtain Proxy Form B can download through the Company's website (<https://jsppharma.com/th/>) and then fill in information, sign over the form and send out the proxy form together with supporting documents as determined in the Enclosure 8 (duty stamp is not required) by following the instruction to attend the Annual General Meeting of Shareholders for the year 2025 and cast the votes via electronic mean (E-AGM) by granting proxy as appeared in the Enclosure 8 or postal to Company Secretary, JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited, 255, 257, Soi Sathupradit 58,

Bangphongphang Sub-District, Yannawa District, Bangkok 10120.

To prepare the readiness prior to the meeting, the Company shall open E-AGM registration system to the Shareholders or proxy to register attending the meeting on 1 April 2025 at 9.00 until 21 April 2025 at 15.00 or until the meeting is finished. The Shareholders of the proxy are able to attend the meeting on 22 April 2025 since 8.00, which is 2 hours prior to the meeting begins. However, the meeting shall only begin on 10.00.

In order to enable the Shareholders have got the highest benefits from the meeting and assist the Board of Directors and management team to prepare information on the meeting date, the Shareholders can send questions in advance prior to the meeting date by indicating name, surname, telephone no. and e-mail (if any) to the Company's Company Secretary via e-mail i.e. ir@jsppharma.com or postage via address as mentioned earlier.

Please be informed accordingly and attend the Meeting at the date, time and methods mentioned above.

Sincerely Yours,

(Ms. Jirada Daengprasert)

Company Secretary

as authorised by the Board of Directors